Huanzheng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huanzheng Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Shaohua Tang
Key Laboratory of Birth Defects Department of Genetics Wenzhou Central Hospital Wenzhou China
3 shared publications Yanbao Xiang
Key Laboratory of Birth Defects, Department of Genetics Wenzhou Central Hospital Wenzhou China
3 shared publicationsChenyang Xu
Wenzhou Central Hospital Wenzhou China
2 shared publicationsLili Zhou
Wenzhou Central Hospital Wenzhou China
2 shared publicationsXiaohua Tang
Wenzhou Central Hospital Wenzhou China
2 shared publicationsXueqin Xu
Wenzhou Central Hospital Wenzhou China
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (10) , e70324
Prenatal Diagnosis and Postnatal Follow‐Up of 19 Fetuses With 16p13.11 Microduplication in a Cohort of 12,038 Pregnancies From South Zhejiang
Background: Prenatal interpretation of 16p13.11 microduplication remains difficult in daily practice, mainly because the same duplication may be associated with very different clinical outcomes. In this study, we reviewed fetuses diagnosed with 16p13.11 microduplication at our center and summarized their prenatal findings, pregnancy outcomes, and postnatal development to provide data that may be useful in prenatal counseling. Methods: We retrospectively reviewed 12,038 pregnant women who underwent amniocentesis at Wenzhou Central Hospital between 2014 and 2025. Chromosomal microarray analysis was performed in all cases. For fetuses carrying 16p13.11 microduplication, we reviewed the indication for amniocentesis, ultrasound findings, pregnancy outcome, and available postnatal follow‐up information. Results: Chromosomal microarray analysis (CMA) identified 16p13.11 microduplication in 19 fetuses, with duplication sizes ranging from 0.80 to 1.60 Mb. The main indications for prenatal diagnosis were advanced maternal age ( n = 7), adverse pregnancy history ( n = 5), ultrasound abnormalities ( n = 4), and high‐risk serum screening results ( n = 3). Three pregnancies were terminated. Sixteen infants were live‐born, of whom two were lost to follow‐up. Among the remaining 14 children, the follow‐up period ranged from 10 months to 10 years. One infant was hospitalized at birth for a ventricular septal defect, and one child showed growth and developmental delay. Five children showed better growth and development than their peers, whereas seven had no apparent abnormalities during follow‐up. Conclusion: The follow‐up results in our cohort are consistent with the incomplete penetrance and variable outcomes reported for 16p13.11 microduplication. In this cohort, most live‐born children showed mild or no clinical manifestations. In prenatal counseling, this CNV should be discussed together with fetal imaging results, inheritance pattern, family history, and available follow‐up data rather than interpreted as an isolated finding.
- 15 October 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (10) , e70324
Open AccessPrenatal Diagnosis and Postnatal Follow‐Up of 19 Fetuses With 16p13.11 Microduplication in a Cohort of 12,038 Pregnancies From South Zhejiang
Background: Prenatal interpretation of 16p13.11 microduplication remains difficult in daily practice, mainly because the same duplication may be associated with very different clinical outcomes. In this study, we reviewed fetuses diagnosed with 16p13.11 microduplication at our center and summarized their prenatal findings, pregnancy outcomes, and postnatal development to provide data that may be useful in prenatal counseling. Methods: We retrospectively reviewed 12,038 pregnant women who underwent amniocentesis at Wenzhou Central Hospital between 2014 and 2025. Chromosomal microarray analysis was performed in all cases. For fetuses carrying 16p13.11 microduplication, we reviewed the indication for amniocentesis, ultrasound findings, pregnancy outcome, and available postnatal follow‐up information. Results: Chromosomal microarray analysis (CMA) identified 16p13.11 microduplication in 19 fetuses, with duplication sizes ranging from 0.80 to 1.60 Mb. The main indications for prenatal diagnosis were advanced maternal age ( n = 7), adverse pregnancy history ( n = 5), ultrasound abnormalities ( n = 4), and high‐risk serum screening results ( n = 3). Three pregnancies were terminated. Sixteen infants were live‐born, of whom two were lost to follow‐up. Among the remaining 14 children, the follow‐up period ranged from 10 months to 10 years. One infant was hospitalized at birth for a ventricular septal defect, and one child showed growth and developmental delay. Five children showed better growth and development than their peers, whereas seven had no apparent abnormalities during follow‐up. Conclusion: The follow‐up results in our cohort are consistent with the incomplete penetrance and variable outcomes reported for 16p13.11 microduplication. In this cohort, most live‐born children showed mild or no clinical manifestations. In prenatal counseling, this CNV should be discussed together with fetal imaging results, inheritance pattern, family history, and available follow‐up data rather than interpreted as an isolated finding.
- Open Access
- 8 June 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (6) , e70241
Differential Transcriptome Analysis of Intrauterine UPD6pat Fetuses With Distinct Phenotypes
Objective: Uniparental disomy of chromosome 6, typically paternal in origin (UPD6pat), results in significant phenotypic variability across different cases. This study integrates transcriptome‐wide profiling of amniotic fluid cell‐free RNA (cfRNA) with molecular diagnostics to elucidate the gene expression landscape and pathway dysregulation in two phenotypically distinct UPD6pat cases. Methods: RNA sequencing (RNA‐seq) was performed on amniotic fluid supernatants from two UPD6pat fetuses and two gestational age‐matched controls. Results: Differential expression analysis revealed 372 significantly dysregulated genes (242 upregulated and 130 downregulated; p < 0.05, |logFC| ≥ 0.5) enriched in pathways related to glucose metabolism, neurodegenerative diseases, and cellular processes. Gene set enrichment analysis (GSEA) further highlighted UPD6pat‐associated perturbations in type 1 diabetes and glycosylphosphatidylinositol biosynthesis pathways. Phenotype‐specific analysis revealed opposing expression trends in growth restriction genes and clubfoot‐related genes (EP300 and CHD7), with protein–protein interaction (PPI) networks implicating epigenetic modulation and cytoskeletal dynamics as potential drivers of phenotypic divergence. Conclusion: Despite limitations in sample size, our findings underscore the utility of amniotic fluid cfRNA analysis as a noninvasive tool for prenatal diagnostics and highlight novel targets for further functional validation.
- 8 June 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (6) , e70241
Open AccessDifferential Transcriptome Analysis of Intrauterine UPD6pat Fetuses With Distinct Phenotypes
Objective: Uniparental disomy of chromosome 6, typically paternal in origin (UPD6pat), results in significant phenotypic variability across different cases. This study integrates transcriptome‐wide profiling of amniotic fluid cell‐free RNA (cfRNA) with molecular diagnostics to elucidate the gene expression landscape and pathway dysregulation in two phenotypically distinct UPD6pat cases. Methods: RNA sequencing (RNA‐seq) was performed on amniotic fluid supernatants from two UPD6pat fetuses and two gestational age‐matched controls. Results: Differential expression analysis revealed 372 significantly dysregulated genes (242 upregulated and 130 downregulated; p < 0.05, |logFC| ≥ 0.5) enriched in pathways related to glucose metabolism, neurodegenerative diseases, and cellular processes. Gene set enrichment analysis (GSEA) further highlighted UPD6pat‐associated perturbations in type 1 diabetes and glycosylphosphatidylinositol biosynthesis pathways. Phenotype‐specific analysis revealed opposing expression trends in growth restriction genes and clubfoot‐related genes (EP300 and CHD7), with protein–protein interaction (PPI) networks implicating epigenetic modulation and cytoskeletal dynamics as potential drivers of phenotypic divergence. Conclusion: Despite limitations in sample size, our findings underscore the utility of amniotic fluid cfRNA analysis as a noninvasive tool for prenatal diagnostics and highlight novel targets for further functional validation.
- Open Access
- 23 February 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (2) , e70064
Saliva Sample‐Based Non‐Invasive Carrier Screening for Spinal Muscular Atrophy, Hereditary Hearing Loss, and Thalassemia in 13,926 Women of Reproductive Age From South Zhejiang
Background: Although spinal muscular atrophy (SMA), hereditary hearing loss (HL), and thalassemia are common monogenic genetic diseases, the carrier frequencies and variant spectrums of these diseases show regional differences, even within China. Their carrier frequencies and variant spectrums in Southern Zhejiang, China are unclear.Methods: Saliva was collected for carrier screening and amniotic fluid, villi, and peripheral blood were collected for prenatal diagnosis. Real‐time quantitative polymerase chain reaction (PCR) and multiplex ligation‐dependent probe amplification (MLPA) were used to detect the copy number of SMN1 exon 7. PCR coupled with flow‐through hybridization, MLPA, and Sanger sequencing were used to detect common genes for HL and thalassemia.Results: Common variants were detected in 15.14% (2109/13926) of the 13,926 women of reproductive age from South Zhejiang who participated in this study. The carrier frequencies of SMA, HL, and thalassemia were 2.11% (294/13926), 4.87% (678/13926), and 8.82% (1228/13926), respectively. In total, 56.47% (1117/1978) of husbands were successfully recalled. The total number of at‐risk couples was 111 (111/13926, 0.80%). Further, 47 families underwent prenatal diagnosis. A total of 13 (13/13926; 0.93‰) affected pregnancies were identified.Conclusion: Our findings confirm that SMA, HL, and thalassemia are highly prevalent in Southern Zhejiang, with some regional specificity, as compared with recent large population‐based surveys in China. Further, a rapid saliva sample‐based non‐invasive screening method was established, and its feasibility was demonstrated.
- 23 February 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (2) , e70064
Open AccessSaliva Sample‐Based Non‐Invasive Carrier Screening for Spinal Muscular Atrophy, Hereditary Hearing Loss, and Thalassemia in 13,926 Women of Reproductive Age From South Zhejiang
Background: Although spinal muscular atrophy (SMA), hereditary hearing loss (HL), and thalassemia are common monogenic genetic diseases, the carrier frequencies and variant spectrums of these diseases show regional differences, even within China. Their carrier frequencies and variant spectrums in Southern Zhejiang, China are unclear.Methods: Saliva was collected for carrier screening and amniotic fluid, villi, and peripheral blood were collected for prenatal diagnosis. Real‐time quantitative polymerase chain reaction (PCR) and multiplex ligation‐dependent probe amplification (MLPA) were used to detect the copy number of SMN1 exon 7. PCR coupled with flow‐through hybridization, MLPA, and Sanger sequencing were used to detect common genes for HL and thalassemia.Results: Common variants were detected in 15.14% (2109/13926) of the 13,926 women of reproductive age from South Zhejiang who participated in this study. The carrier frequencies of SMA, HL, and thalassemia were 2.11% (294/13926), 4.87% (678/13926), and 8.82% (1228/13926), respectively. In total, 56.47% (1117/1978) of husbands were successfully recalled. The total number of at‐risk couples was 111 (111/13926, 0.80%). Further, 47 families underwent prenatal diagnosis. A total of 13 (13/13926; 0.93‰) affected pregnancies were identified.Conclusion: Our findings confirm that SMA, HL, and thalassemia are highly prevalent in Southern Zhejiang, with some regional specificity, as compared with recent large population‐based surveys in China. Further, a rapid saliva sample‐based non‐invasive screening method was established, and its feasibility was demonstrated.
- Open Access
- 7 August 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (21) , 3286-3295
PLPPR4 haploinsufficiency causes neurodevelopmental disorders by disrupting synaptic plasticity via mTOR signalling
Phospholipid phosphatase related 4 (PLPPR4), a neuron‐specific membrane protein located at the postsynaptic density of glutamatergic synapses, is a putative regulator of neuronal plasticity. However, PLPPR4 dysfunction has not been linked to genetic disorders. In this study, we report three unrelated patients with intellectual disability (ID) or autism spectrum disorder (ASD) who harbour a de novo heterozygous copy number loss of PLPPR4 in 1p21.2p21.3, a heterozygous nonsense mutation in PLPPR4 (NM_014839, c.4C > T, p.Gln2*) and a homozygous splice mutation in PLPPR4 (NM_014839: c.408 + 2 T > C), respectively. Bionano single‐molecule optical mapping confirmed PLPPR4 deletion contains no additional pathogenic genes. Our results suggested that the loss of function of PLPPR4 is associated with neurodevelopmental disorders. To test the pathogenesis of PLPPR4, peripheral blood mononuclear cells obtained from the patient with heterozygous deletion of PLPPR4 were induced to specific iPSCs (CHWi001‐A) and then differentiated into neurons. The neurons carrying the deletion of PLPPR4 displayed the reduced density of dendritic protrusions, shorter neurites and reduced axon length, suggesting the causal role of PLPPR4 in neurodevelopmental disorders. As the mTOR signalling pathway was essential for regulating the axon maturation and function, we found that mTOR signalling was inhibited with a higher level of p‐AKT, p‐mTOR and p‐ERK1/2, decreased p‐PI3K in PLPPR4‐iPSCs neurons. Additionally, we found silencing PLPPR4 disturbed the mTOR signalling pathway. Our results suggested PLPPR4 modulates neurodevelopment by affecting the plasticity of neurons via the mTOR signalling pathway.
- 7 August 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (21) , 3286-3295
Open AccessPLPPR4 haploinsufficiency causes neurodevelopmental disorders by disrupting synaptic plasticity via mTOR signalling
Phospholipid phosphatase related 4 (PLPPR4), a neuron‐specific membrane protein located at the postsynaptic density of glutamatergic synapses, is a putative regulator of neuronal plasticity. However, PLPPR4 dysfunction has not been linked to genetic disorders. In this study, we report three unrelated patients with intellectual disability (ID) or autism spectrum disorder (ASD) who harbour a de novo heterozygous copy number loss of PLPPR4 in 1p21.2p21.3, a heterozygous nonsense mutation in PLPPR4 (NM_014839, c.4C > T, p.Gln2*) and a homozygous splice mutation in PLPPR4 (NM_014839: c.408 + 2 T > C), respectively. Bionano single‐molecule optical mapping confirmed PLPPR4 deletion contains no additional pathogenic genes. Our results suggested that the loss of function of PLPPR4 is associated with neurodevelopmental disorders. To test the pathogenesis of PLPPR4, peripheral blood mononuclear cells obtained from the patient with heterozygous deletion of PLPPR4 were induced to specific iPSCs (CHWi001‐A) and then differentiated into neurons. The neurons carrying the deletion of PLPPR4 displayed the reduced density of dendritic protrusions, shorter neurites and reduced axon length, suggesting the causal role of PLPPR4 in neurodevelopmental disorders. As the mTOR signalling pathway was essential for regulating the axon maturation and function, we found that mTOR signalling was inhibited with a higher level of p‐AKT, p‐mTOR and p‐ERK1/2, decreased p‐PI3K in PLPPR4‐iPSCs neurons. Additionally, we found silencing PLPPR4 disturbed the mTOR signalling pathway. Our results suggested PLPPR4 modulates neurodevelopment by affecting the plasticity of neurons via the mTOR signalling pathway.
- Open Access
- 27 February 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (4) , e1638
Mutation analysis and prenatal diagnosis of a family with congenital contractural arachnodactyly
Background: Congenital contractural arachnodactyly (CCA) is a rare autosomal dominant condition caused by mutations in the fibrillin 2 gene (FBN2). The primary clinical symptoms of CCA include multiple flexion contractures, arachnodactyly, dolichostenomelia, scoliosis, abnormal pinnae, muscular hypoplasia, and crumpled ears.Methods: We used whole‐exome sequencing technology to examine an arthrogryposis multiplex congenita and used Sanger sequencing technology to genetically confirm its family.Results: FBN2 c.3344A>T(p.D1115V) was identified in this family with CCA in a pedigree. Prenatal diagnosis and counseling were carried out simultaneously to avoid the birth of the sick fetus.Conclusion: The study is on FBN2 variant in CCA, which potentially having implications for genetic counseling and clinical management, our study may provide new insights into the cause and diagnosis of CCA.
- 27 February 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (4) , e1638
Open AccessMutation analysis and prenatal diagnosis of a family with congenital contractural arachnodactyly
Background: Congenital contractural arachnodactyly (CCA) is a rare autosomal dominant condition caused by mutations in the fibrillin 2 gene (FBN2). The primary clinical symptoms of CCA include multiple flexion contractures, arachnodactyly, dolichostenomelia, scoliosis, abnormal pinnae, muscular hypoplasia, and crumpled ears.Methods: We used whole‐exome sequencing technology to examine an arthrogryposis multiplex congenita and used Sanger sequencing technology to genetically confirm its family.Results: FBN2 c.3344A>T(p.D1115V) was identified in this family with CCA in a pedigree. Prenatal diagnosis and counseling were carried out simultaneously to avoid the birth of the sick fetus.Conclusion: The study is on FBN2 variant in CCA, which potentially having implications for genetic counseling and clinical management, our study may provide new insights into the cause and diagnosis of CCA.
- Open Access
- 23 October 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (12) , e1539
Next‐generation sequencing identifies rare pathogenic and novel candidate variants in a cohort of Chinese patients with syndromic or nonsyndromic hearing loss
Background: Hearing loss (HL) is a common sensory disorder in humans characterized by extreme clinical and genetic heterogeneity. In recent years, next‐generation sequencing (NGS) technologies have proven to be highly effective and powerful tools for population genetic studies of HL. Here, we analyzed clinical and molecular data from 21 Chinese deaf families who did not have hotspot mutations in the common deafness genes GJB2, SLC26A4, GJB3, and MT‐RNR1.Method: Targeted next‐generation sequencing (TGS) of 127 known deafness genes was performed in probands of 12 families, while whole‐exome sequencing (WES) or trio‐WES was used for the remaining nine families.Results: Potential pathogenic mutations in a total of 12 deafness genes were identified in 13 probands; the mutations were observed in GJB2, CDH23, EDNRB, MYO15A, OTOA, OTOF, TBC1D24, SALL1, TMC1, TWNK, USH1C, and USH1G, with eight of the identified mutations being novel. Further, a copy number variant (CNV) was detected in one proband with heterozygous deletion of chromosome 4p16.3‐4p15.32. Thus, the total diagnostic rate using NGS in our deafness patients reached 66.67% (14/21).Conclusions: These results expand the mutation spectrum of deafness‐causing genes and provide support for the use of NGS detection technologies for routine molecular diagnosis in Chinese deaf populations.
- 23 October 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (12) , e1539
Open AccessNext‐generation sequencing identifies rare pathogenic and novel candidate variants in a cohort of Chinese patients with syndromic or nonsyndromic hearing loss
Background: Hearing loss (HL) is a common sensory disorder in humans characterized by extreme clinical and genetic heterogeneity. In recent years, next‐generation sequencing (NGS) technologies have proven to be highly effective and powerful tools for population genetic studies of HL. Here, we analyzed clinical and molecular data from 21 Chinese deaf families who did not have hotspot mutations in the common deafness genes GJB2, SLC26A4, GJB3, and MT‐RNR1.Method: Targeted next‐generation sequencing (TGS) of 127 known deafness genes was performed in probands of 12 families, while whole‐exome sequencing (WES) or trio‐WES was used for the remaining nine families.Results: Potential pathogenic mutations in a total of 12 deafness genes were identified in 13 probands; the mutations were observed in GJB2, CDH23, EDNRB, MYO15A, OTOA, OTOF, TBC1D24, SALL1, TMC1, TWNK, USH1C, and USH1G, with eight of the identified mutations being novel. Further, a copy number variant (CNV) was detected in one proband with heterozygous deletion of chromosome 4p16.3‐4p15.32. Thus, the total diagnostic rate using NGS in our deafness patients reached 66.67% (14/21).Conclusions: These results expand the mutation spectrum of deafness‐causing genes and provide support for the use of NGS detection technologies for routine molecular diagnosis in Chinese deaf populations.